MARKET

CING

CING

Cingulate Inc
NASDAQ
4.320
+0.020
+0.47%
After Hours: 4.300 -0.02 -0.46% 16:42 05/02 EDT
OPEN
4.300
PREV CLOSE
4.300
HIGH
4.410
LOW
4.250
VOLUME
39.05K
TURNOVER
--
52 WEEK HIGH
20.83
52 WEEK LOW
1.800
MARKET CAP
17.03M
P/E (TTM)
-0.4237
1D
5D
1M
3M
1Y
5Y
1D
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301
TipRanks · 4d ago
Roth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)
TipRanks · 4d ago
Cingulate announces results from high-dose fed/fast study of CTx-1301
TipRanks · 5d ago
CINGULATE ANNOUNCES POSITIVE TOP-LINE RESULTS FROM HIGH-DOSE (50MG) FED/FAST STUDY OF LEAD ASSET CTX-1301 FOR ADHD
Reuters · 5d ago
Weekly Report: what happened at CING last week (0421-0425)?
Weekly Report · 6d ago
Cingulate Is Maintained at Buy by Ascendiant Capital
Dow Jones · 04/21 10:44
Cingulate Price Target Cut to $60.00/Share From $75.00 by Ascendiant Capital
Dow Jones · 04/21 10:44
Weekly Report: what happened at CING last week (0414-0418)?
Weekly Report · 04/21 09:54
More
About CING
More
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Recently
Symbol
Price
%Change

Webull offers Cingulate Inc stock information, including NASDAQ: CING real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CING stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CING stock methods without spending real money on the virtual paper trading platform.